Population aging and unhealthy lifestyles have led to a growing population of patients with metabolic diseases. The pathogenesis of many chronic metabolic diseases such as obesity, diabetes, fatty liver, gout, etc., caused by disorders in carbohydrate, lipid, and protein metabolism is particularly complex, with numerous risk factors, and patients often suffer from multiple complications or comorbidities. The pursuit of clinical multiple benefits and reducing the long-term burden of medication has become the key focus of current drug treatment. Based on research in this market, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') has released 'Research on the Market for Innovative Medications for Metabolic Diseases'.
The above content is only a report summary. For more information, please contact us. Thank you!
